HomeProductsBioactive CompoundsAnti-Infective AgentsAntibacterial AgentsRabeprazole
Chemical structure of CAS 117976-89-3

Rabeprazole

In Stock•Starting at $13 for 1 mg•Purity ≥ 98%
CAS No.117976-89-3
MDL No.MFCD00868879
MFC18H21N3O3S
MW359.40
InChI KeyYREYEVIYCVEVJK-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$13In Stock
50 mg98%$128In Stock
100 mg98%$187In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Rabeprazole is a benzimidazole, sulfoxide, and pyridine derivative. It functions as an H(+)/K(+)-exchanging ATPase inhibitor and an anti-ulcer drug. It is the conjugate acid of rabeprazole(1-).

CAS No.117976-89-3
Product NameRabeprazole

Biological Targets

ATP4A·ATP4B

Associated Conditions

amyotrophic lateral sclerosis·Helicobacter pylori infectious disease·dyspepsia·duodenal ulcer·lymphoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.

Alimentary pharmacology & therapeutics • Vol. 15, Issue 2 • 2001
PMID: 11148433DOI: 10.1046/j.1365-2036.2001.00923.x

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.

Alimentary pharmacology & therapeutics • Vol. 15, Issue 3 • 2001
PMID: 11207518DOI: 10.1046/j.1365-2036.2001.00929.x

[Selection of antibiotics and planning of eradication for H. pylori infection].

Nihon rinsho. Japanese journal of clinical medicine • Vol. 59, Issue 2 • 2001
PMID: 11218403

Efficacy of rabeprazole once daily for acid-related disorders.

Digestive diseases and sciences • Vol. 46, Issue 3 • 2001
PMID: 11318537DOI: 10.1023/a:1005659518030

Documentation

Similar Products